Omnix Medical advances first-in-class antimicrobial OMN6 into Phase II trials
Targeting deadly drug-resistant acinetobacter infections
Targeting deadly drug-resistant acinetobacter infections
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Subscribe To Our Newsletter & Stay Updated